Perforomist-Comparable Pharmacokinetic And Pharmacodynamic Profile To DPI Formulation
Data presented at the International Forum of the American Thoracic Society (ATS) expose that Perforomist™ Inhalation Solution (formoterol fumarate inhalation solution; FFIS) has a pharmacodynamic and pharmacokinetic profile that is comparable to the unadorned powder inhaler (DPI) formulation of formoterol fumarate, Foradil® Aerolizer® 12 µg (FA).
Perforomist™ (formoterol fumarate) Inhalation Explication, the solitary FDA-approved nebulized formoterol fumarate, was approved in 2007 by the FDA for wish-footing, twice-daily upkeep treatment of bronchoconstriction in patients with dyed in the wool obstructive pulmonary affliction (COPD), including chronic bronchitis and emphysema.
The triumph of the two studies presented, “Dose-Ranging Study in COPD Patients Comparing Pharmacodynamics of Formoterol Fumarate Delivered by Nebulization and DPI,” showed that 20 µg of FFIS (Perforomist™ Inhalation Solution) delivered by nebulization provides bronchodilation comparable to DPI delivery.
The following study; “A Pharmacokinetic Study in COPD Patients Comparing Formoterol Fumarate Delivered by Nebulization and DPI,” showed comparability in linear kinetics and excreted stupefy levels between formoterol fumarate administered by nebulization and DPI. Transient and dose-linked effects on serum potassium, serum glucose and critical signs were observed and found to be comparable between the two formulations.
Dr. Nicholas J. Gross, MD, PhD, Hines VA Hospital, Stricht Loyola School of Nostrum and main clinical investigator in the first study, commented, “The results of both of these studies take measures additional evidence of the clinical benefit of Perforomist™ Inhalation Solution as a valuable treatment option for patients with COPD. Nebulization is an alternative moving to deliver medication to the lungs and since myriad patients may have difficulty coordinating the use of other devices as their contagion progresses, nebulized Perforomist™ offers an effective, hanker-term treatment option.”
The in the first place examination was a single-dispense, double-hide, deceitful-dummy crossover dose-ranging bone up on conducted in 47 patients to establish the measure of Perforomist™ Inhalation Solution comparable to that of the marketed DPI, Foradil® Aerolizer®. Mean FEV1 AUC0-12 (standardized area under the curve for FEV1 over twelve hours) following FFIS treatment ranged from 1.3 to 3.0 L/hr in a dose-tied up manner, with identical values (2.3 L/hr) for Perforomist™ Inhalation Resolution 20 µg and Foradil® Aerolizer®. All other spirometry measures were comparable between FFIS and FA.
The second study involving thirteen COPD patients was a randomized, single-prescribe, open-label, crossover study comparing FFIS 10, 20, and 24 µg with Foradil® Aerolizer®, which confirmed pharmacokinetic comparability between Perforomist™ Inhalation Unravelling 20 µg by nebulization and Foradil® Aerolizer® 12 µg (Foradil) by DPI.
“This research continues to support and highlight the clinical value of Perforomist™ Inhalation Solution,” said Carolyn Myers, Ph.D., President of Dey, L.P. “We show one’s gratitude all of these well-known researchers for their contributions to the trials that were presented today and we remain dedicated to developing nebulized treatment options for those suffering from nasty respiratory illnesses such as COPD.”
—————————-
Article adapted by Medical News Today from original press release.
—————————-
Circular Session ID C42 COPD Pharmacotherapy I: Effects of Bronchodilators
- Poster #F13: Dose-Ranging Study in COPD Patients Comparing Pharmacodynamics of Formoterol Fumarate Delivered by Nebulization and DPI
- Poster #F14: A Pharmacokinetic Study in COPD Patients Comparing Formoterol Fumarate Delivered by Nebulization and DPI
The investigate presented at ATS 2008 was supported through grants provided by Dey, L.P., which developed and markets Perforomist™ Inhalation Liquid. Dey, L.P. is a subsidiary of Mylan Inc. (NYSE: MYL).
About Perforomist™ Inhalation Solution
Indication
Perforomist™ Inhalation Mixture is indicated in behalf of the long-word, twice-daily (morning and evening) authority in the stipend treatment of bronchoconstriction in patients with chronic obstructive pulmonary affliction (COPD) including dyed in the wool bronchitis and emphysema.
Important Protection Information
Perforomist™ Inhalation Solution belongs to a sort of medications known as long-acting beta2-adrenergic agonists (LABAs). LABAs may increase the risk of asthma-agnate annihilation. Figures from a large placebo-controlled US analyse comparing the safety of another LABA (salmeterol) or placebo added to usual asthma group therapy showed an developing in asthma-related deaths in patients receiving salmeterol. This discovery with salmeterol may bid to formoterol (a LABA), the active ingredient in Perforomist™ Inhalation Solution.
Perforomist™ Inhalation Solution should not be occupied in patients with acutely deteriorating COPD or to treat serious symptoms. Acute symptoms should be treated with tightly-acting rescue inhalers. Perforomist™ Inhalation Colloid should not be used with other medications containing LABAs. Do not utility more than one nebule twice daily. Perforomist™ Inhalation Solution should be used with caution in patients with cardiovascular disorders. Perforomist™ Inhalation Solution is not a substitute for inhaled or verbal corticosteroids. The safety and efficacy of Perforomist™ Inhalation Emulsion in asthma has not been established.
In COPD clinical trials, the most common adverse events reported with Perforomist™ Inhalation Explanation were diarrhea, nausea, nasopharyngitis, dry mouth, vomiting, dizziness, and insomnia.
Interest conduct highest Prescribing Information, including Boxed Warning, at http://www.perforomist.com/.
Upon COPD
COPD refers to a tons of chronic lung disorders in which the airways to the lungs become narrowed and breathing becomes increasingly obscure. The most common forms of COPD are inveterate bronchitis and emphysema and many patients suffer from a combination of the two diseases.
COPD is the fourth foremost occasion of annihilation in America, behind heart disease, cancer and thump. Twelve million Americans have been diagnosed with COPD and at least another 12 million have symptoms but require not been diagnosed. COPD is not well conceded or recognized - most Americans have not heard of it, not square those who may be living with the environment. The most common issue of COPD is cigarette smoking, which is answerable as an estimated 80 to 90 percent of COPD cases. Estimates of the total quantity of COPD in America range from 24 to 30 million.
Thither Nebulization
Of the three types of devices used to deliver bronchodilators - nebulizers, metered-prescribe inhalers, and dry triturate inhalers - nebulizers require no special technique or coordination, as the medication is converted into a cool vapour that the patient inhales through a mouthpiece or brass neck-mask while breathing easily. Nebulization is an easy and effective method of delivering nostrum directly into the lungs for patients, particularly as their symptoms go from bad to worse.
With Perforomist™ Inhalation Conclusion, nebulization may become a more thoroughly used treatment option for assorted COPD patients at earlier treatment stages who could benefit from twice-daily maintenance dosing of a nebulized LABA such as Perforomist™ Inhalation Solution. For admonition, this new COPD treatment may be a valuable clinical way out instead of innumerable patients whose symptoms are not adequately controlled with their current therapy. COPD patients should consider asking their doctor whether nebulized treatment may be right for them.
About Dey, L.P.
Dey, L.P., a subsidiary of Mylan Inc. (NYSE: MYL), is a specialty pharmaceutical company focused on the development, manufacturing and marketing of preparation knock out products for the treatment of respiratory diseases, respiratory-interconnected allergies, and difficulty care medicine. As the U.S. bandleader in sales of nebulized respiratory medication, Dey, L.P. puts patients earliest owing to its happening of innovative and affordable therapies. http://www.dey.com/.
Perforomist™ is a trademark of Dey, L.P.
Foradil® Aerolizer® is a registered trademark of Novartis Pharma AG
Source: Amy Techtmann
Feinstein Kean Healthcare
View dull information on Foradil Aerolizer.